Skip to content
All resources

Research

The Future of Oral Peptides: Could Injections Become Less Common?

AR

By

· 5 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 7 sections
  1. Why are peptides difficult to take orally?
  2. Absorption enhancers: improving transport
  3. Molecular engineering and more stable peptides
  4. Oral GLP-1 research shows what is possible
  5. Could smart capsules transform drug delivery?
  6. What changes in 2027?
  7. Further reading

For decades, one of the largest challenges in peptide drug development has been surprisingly simple: getting the molecule into the body intact. Many therapeutic peptides are given by injection because the gastrointestinal tract is built to break down proteins and peptides during digestion.

Pharmaceutical research is working on that limitation. From engineered molecular structures to sophisticated delivery technologies, researchers are developing approaches intended to make oral peptide administration more practical.

A clear capsule split open around a chain of teal beads wrapped in a white protective coating
Illustration: oral delivery has to protect a peptide chain through the gut and still let it be absorbed.

Why are peptides difficult to take orally?

Peptides are chains of amino acids joined by peptide bonds. Their structures let them interact with specific biological targets, but they also create problems for oral administration:

  • Enzymatic degradation. Digestive enzymes can cut peptides into smaller fragments before they reach the circulation.
  • Poor intestinal permeability. Many peptides are relatively large and hydrophilic, so they cross the intestinal lining poorly.
  • Variable absorption. Even when a peptide reaches the intestinal surface, the fraction absorbed can be low and inconsistent.

A 2026 review adds mucus entrapment and presystemic metabolism to that list (Vasović and colleagues, 2026). Overcoming these barriers takes more than putting a peptide in a capsule. It needs a delivery system that protects the molecule while allowing enough of it to be absorbed. The chemistry of breakdown is covered in peptide degradation pathways.

Absorption enhancers: improving transport

Permeation enhancers are designed to help certain molecules cross biological barriers. Some temporarily change the local environment around intestinal epithelial cells; others improve solubility or transport. Sodium caprate is one studied example: a 2026 formulation study used it to develop an experimental oral tirzepatide tablet and measured exposure in dogs (Im and colleagues, 2026), which is a long way from evidence in people.

The challenge is adequate absorption without compromising tissue safety. Researchers have to establish how consistently an enhancer works, how the intestinal barrier recovers, and whether repeated exposure carries risks of its own.

Molecular engineering and more stable peptides

Chemical modification can improve resistance to enzymatic breakdown or change how a molecule interacts with membranes. Researchers are studying cyclization, structural stabilization, modified amino acid sequences, lipidation, protective encapsulation and advanced carrier systems. Macrocyclic peptides designed for oral use, such as MK-0616 and JNJ-77242113, are examples (Niazi, 2026).

These technologies may address several delivery problems at once. But changing a molecule's structure can also change its receptor activity, distribution and safety, so each new design needs its own experimental validation. How structure affects persistence is covered in peptide half-life explained.

Oral GLP-1 research shows what is possible

Oral semaglutide showed that some peptide therapeutics can be given as a tablet with specialized formulation technology. Researchers have since widened the effort to both oral peptides and non-peptide molecules that act at the same receptors.

The two should not be confused. Orforglipron is an oral small-molecule GLP-1 receptor agonist, not a peptide. Its development reflects progress in oral metabolic medicine, but it does not solve the absorption problems faced by conventional peptide structures.

One 2026 review argues that oral semaglutide is a boundary case rather than proof of a platform: its very long half-life, high potency and wide therapeutic window tolerate low and variable absorption, a combination most peptides lack (Niazi, 2026). On that reading, whether a peptide can be oral depends first on its pharmacology and only second on formulation.

Could smart capsules transform drug delivery?

Some experimental technologies go beyond tablets. Researchers are investigating ingestible devices that deliver a drug through mechanical or localized mechanisms, along with nanoparticle carriers, bioinspired systems such as bile acid-inspired carriers, and engineered materials (Vasović and colleagues, 2026). Device-mediated systems that place a drug into the gut wall are a different thing from oral absorption, and are evaluated as combination products whose reliability depends on the device.

These technologies are at very different stages. Wide adoption will depend on manufacturing scale, safety, reliability, cost and demonstrated advantages over existing treatments.

The future of peptide delivery depends on solving a fundamental engineering problem: preserving molecular activity while delivering a reliable amount of the compound to the intended biological target.

What changes in 2027?

The next wave of innovation is likely to be judged on practical performance: whether new systems give consistent exposure, simplify manufacturing and meet regulatory standards. Oral delivery will not necessarily replace injections across the industry, and some molecules may remain better suited to injectable or other routes.

The most important oral peptide breakthrough may not be a new peptide at all. It may be a better way to deliver one.

Nothing here is medical, dosing or therapeutic guidance.

Selected Research References

  1. Vasović S, Vasović L, Martić N, et al. Emerging Technologies for Oral Peptide Delivery: From Bioinspired Systems to Smart Device-Assisted Drug Delivery. Pharmaceuticals. 2026;19(9). pubmed.ncbi.nlm.nih.gov/42797374
  2. Niazi SK. Oral delivery of peptides and proteins: pharmacokinetic boundaries, negative selection, and route triage. Frontiers in Drug Delivery. 2026;6:1776167. pubmed.ncbi.nlm.nih.gov/41939723
  3. Im S, Lee JY, Kim JE. Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets. Pharmaceutics. 2026;18(7). pubmed.ncbi.nlm.nih.gov/42514904

Further reading

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.